Osmotica Pharmaceuticals PLC $ 3.46 -1.28 (-27%)
Volume:
282,380
Avg Vol (1m):
83,911
Market Cap $:
223.22 Mil
Enterprise Value $:
434.66 Mil
P/E (TTM):
0.00
P/B:
0.83
| Net Current Asset Value | ||
| Tangible Book | ||
| Median P/S Value | ||
|
Price: $3.46 | ||
Manual of Stocks™ Web
Financial Strength | 3.6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.23 | ||
| Equity-to-Asset | 0.4 | ||
| Debt-to-Equity | 1.07 | ||
| Debt-to-EBITDA | -1.64 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | -0.91 | ||
| Beneish M-Score | -2.89 | ||
Profitability | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -6.22 | ||
| Net Margin % | -97.96 | ||
| ROE % | -64.95 | ||
| ROA % | -30.75 | ||
| ROC (Joel Greenblatt) % | -613.06 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 0.83 | ||
| PS Ratio | 0.86 | ||
| Price-to-Free-Cash-Flow | 7.51 | ||
| Price-to-Operating-Cash-Flow | 6.65 | ||
| EV-to-EBIT | -1.79 | ||
| EV-to-EBITDA | -2.53 | ||
| EV-to-Revenue | 1.72 | ||
| Current Ratio | 1.78 | ||
| Quick Ratio | 1.49 | ||
| Days Inventory | 74.84 | ||
| Days Sales Outstanding | 100.82 | ||
| Days Payable | 53.75 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History |
|---|
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Median-PS-Value | 1.12 | ||
| Earnings Yield (Greenblatt) % | -56.23 |